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Abstract
Background: Although several new drugs have been approved in recent years, pulmonary arterial hypertension
(PAH) remains a rapidly progressive disease with a poor prognosis. Ambrisentan, a selective endothelin type A
antagonist, has been approved for treatment of PAH. This open label study assessed the efficacy and safety of
ambrisentan in Chinese subjects with PAH.
Methods: Eligible patients with PAH (World Health Organisation [WHO] functional class [FC] II orIII) were enrolled
and received Ambrisentan (5 mg) once daily for a 12-week preliminary evaluation period, and a 12-week dose-
adjustment period (dose titration to 10 mgallowed). Endpoints included: change from baseline in 6-Minute Walk
Distance (6-MWD), N-Terminal Pro B-Type Natriuretic Peptide (NT-pro-BNP), WHO FC, Borg Dyspnoea Index (BDI),
clinical worsening of PAH and incidences of adverse events (AE).
Results: One hundred thirty-three subjects (85 % women, mean age: 36 years) with PAH (WHOFC II or III) were
enrolled and received ambrisentan (5 mg) once daily for a 12-week preliminary evaluation period, and a 12-week
dose-adjustment period. Mean (SD) duration of drug exposure was 161.7 (27.13) days. Ambrisentan (average daily
dose of 6.27 mg) significantly improved exercise capacity (6MWD) from baseline (mean: 377.1 m [m]) at week 12
(+53.6 m, p < 0.001) (primary endpoint). Improvement in exercise capacity was noted as early as week 4, and was
sustained up to week 24 (+ 64.4 m, p < 0.001). NT-pro-BNP plasma levels decreased significantly (p < 0.001) at week
12 (−861.4 ng/L) and week 24 (−806 ng/L) from baseline (mean: 1600.7 ng/L). The WHO FC showed improvements
for 44 subjects at week 12 and 51 subjects at week 24. BDI scores decreased significantly at week 12 (−0.3, p < 0.
001) and week 24 (−0.2, p = 0.003) from baseline (mean: 2.5). Four patients died during the study (sudden cardiac
death [n = 2], cerebral haemorrhage
[n = 1], cardiac failure [n = 1]). Drug related adverse events occurred in 34.3 % of subjects; peripheral oedema
(11.2 %) and flushing (8.2 %) occurred most frequently.
Conclusion: Ambrisentan (5 and 10 mg, orally) significantly improved the exercise capacity in Chinese PAH subjects
with a safety profile similar to that observed in global studies.
Trial registration: NCT No. (ClinicalTrials.gov): NCT01808313; Registration date (first time): February 28, 2013.
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Background
Pulmonary arterial hypertension (PAH) is a fatal vascular
disease that entails a complex, multifactorial pathophysi-
ology. It is characterised by vascular remodelling and a
progressive increase in pulmonary vascular resistance,
which eventually leads to right ventricular failure and
premature death [1, 2]. An estimated incidence of 2
cases per million individuals every year has been re-
ported for PAH [3]. Life expectancy of untreated PAH
patients is not more than 2–5 years, with 1-year mortal-
ity rate of 15 to 32 % ([3–5]). The majority of the deaths
reported in PAH patients are either due to sudden death
or right-sided heart failure [6].
The therapeutic armamentarium for PAH is evolving
continuously to explore new targets involved in patho-
biological pathways of the disease process. At present,
there are 4 categories of drugs approved globally for
treating PAH: 1) prostaglandin analogues – act via
prostacyclin pathway, 2) phosphodiesterase type-5 inhib-
itors - act via nitric oxide pathway, 3) endothelin recep-
tor antagonist (ERA) – act via endothelin pathway [2]
and 4) soluble cGMP stimulator–act via NO pathway.
Ambrisentan, an endothelin –A (ETA) receptor- select-
ive antagonist, is approved in the United States (US)
(http://www.accessdata.fda.gov/), European Union (EU)
(http://www.ema.europa.eu/) and many other countries
to treat PAH patients with World Health Organisation
(WHO) functional class (FC) II or III symptoms at oral
doses of 5 and 10 mg once daily. Ambrisentan demon-
strated significant efficacy on exercise capacity [7] with a
survival rate of 94 % and a freedom from clinical wors-
ening of 83 % at 1 year follow up [8]. The safety profile
of ambrisentan is well-established and generally includes
adverse events of peripheral oedema, nasal congestion,
sinusitis, flushing, palpitations, nasopharyngitis, abdom-
inal pain and constipation [9]. The adverse events asso-
ciated with ambrisentan treatment are mostly of mild or
moderate severity; Elevations of liver aminotransferases
have been reported with ambrisentan and serious liver
injury has been reported with related drugs, however in
ARIES-1 and ARIES-2 studies, the reported incidence of
aminotransferase elevations >3 × upper limit of nor-
mal (ULN) were 0 % on ambrisentan and 2.3 % on
placebo. In ARIES-E study, twelve patients experi-
enced ALT/AST >3 × ULN during the 2-year period
[7, 8]. Ambrisentan may cause fetal harm if taken
during pregnancy [9].
The pivotal studies that have been reported for ambri-
sentan were predominantly performed in white/cauca-
sian population, the proportion of Asians being very
low. Large variations in metabolism, efficacy and safety
profile of drugs have been noted among individuals from
varied racial and ethnic groups [10], suggesting that the
clinical response to a drug therapy may change based on
the ethnic/racial differences. Therefore, it becomes very
important to account for these differences when clinic-
ally managing individuals from different ethnicities to
provide a rationale therapeutic approach. Lack of big
scale population based clinical data for ambrisentan in
the Asian population has triggered more ethnic-specific
clinical trials to identify specific therapeutic needs in this
population.
This study investigated the efficacy and safety of
ambrisentan in subjects with PAH from China where it
has been conditionally approved for the treatment of
WHO FC II or III PAH. The results of this study add to
the existing clinical information for ambrisentan in




This open label, phase IIIb, single-arm study was con-
ducted from 21 December 2012 to 15 August 2014 at 12
centres in China. Following a 4-week screening period,
eligible subjects received 5 mg ambrisentan orally once
daily for a 12-week primary evaluation period. Subjects
then proceeded to a 12-week dose adjustment period
during which dose titration to 10 mg was allowed. The
total duration of study was 28 weeks.
Study population
Chinese subjects of either gender, aged 18–75 years, di-
agnosed with PAH (WHO FC II or III) categorised in
Group 1 of the WHO Updated Clinical Classification of
Pulmonary Hypertension [1] were enrolled in the study.
All subjects had to perform the 6 min walk test (6MWT)
with a minimum distance of 150 m and maximum distance
of 450 m. Additionally, results from a right heart catherisa-
tion performed within 6 months of screening had to dem-
onstrate mean pulmonary artery pressure ≥25 mmHg;
pulmonary vascular resistance ≥240 dyn/s/cm5; and pul-
monary arterial wedge pressure or left ventricular end-
diastolic pressure ≤15 mmHg. Additional requirements at
entry into the study were total lung capacity ≥60 % and
forced expiratory volume per second (FEV1) ≥55 % of pre-
dicted normal values.
The key exclusion criteria were: serum alanine ami-
notransferase (ALT) or aspartate aminotransferase
(AST) values greater than 2 times ULN, serum biliru-
bin value greater than 1.5 times ULN, haemoglobin
concentration <10 g/dL or haematocrit <30 %, severe
hypotension (diastolic blood pressure <50 mmHg or
systolic blood pressure <90 mmHg), clinically significant
aortic or mitral valve disease, pericardial constriction, re-
strictive or congestive cardiomyopathy, life-threatening car-
diac arrhythmias, left ventricular ejection fraction <45 %,
left ventricular outflow obstruction, symptomatic coronary
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artery disease, autonomic hypotension or fluid depletion,
and severe hepatic and renal impairment.
Also subjects who received prohibited medications
including marketed ambrisentan, bosentan, phospho-
diesterase −5 inhibitor, prostanoids, intravenous ino-
tropes, and nitric oxide were excluded from the study.
The use of calcium channel blockers (CCB) and statins
were permitted only if the subjects were on stable doses
for at least 4 and 12 weeks, respectively, before screening.
Women of childbearing potential had to use medically ac-
ceptable method of contraception (such as hormonal
method, intrauterine device, barrier methods such as
condom or occlusive cap) during the study; pregnant and
lactating women were excluded.
The study was conducted in accordance with ICH
GCP and all applicable patient privacy requirements,
and, the ethical principles that are outlined in the Dec-
laration of Helsinki. The study has received ethical ap-
proval from multiple Independent Ethnics Committees
(IECs) and that the name of these can be found in Add-
itional file 1. The protocol and protocol amendments
were also approved by institutional ethics committee of
each study centre. Written informed consent was ob-
tained from subjects prior to start of the study, the
names of all IECs can be found in the Additional file 1.
Assessments
The primary efficacy endpoint was the change from
baseline to week 12 in the exercise capacity, as measured
by the 6 min walk distance (6MWD) [11–13]. Addition-
ally, the change from baseline to week 24 in 6MWD and
the changes from baseline to week 12 and 24 in NT-
proBNP plasma levels, WHO FC, and BDI score were
assessed as secondary endpoints [14–16]. Echocardiog-
raphy assessments were also performed, which included
evaluation of prognostic factors such as pericardial effu-
sion, tricuspid annular plane systolic excursion (TAPSE)
and eccentricity index. Efficacy parameters (6MWD,
WHO FC and BDI) were evaluated at the following
time points: day 0 (predose [baseline]) and week 4, 8,
12, 16, 20 and 24 postdose. NT-pro BNP plasma
levels and echocardiography parameters were assessed
at baseline, week 12 and 24. Safety assessments in-
cluded evaluation of time to clinical worsening of
PAH, which was defined as the time from baseline to
the first occurrence of death, lung transplantation,
hospitalisation for PAH treatment, atrial septostomy
or ambrisentan discontinuation due to change to
other PAH treatment. Additionally, incidences and
severity of adverse events (AEs), laboratory evalua-
tions, liver function test, vital sign measurements,
12-lead electrocardiogram and physical examination
were performed.
Statistical analysis
Assuming a dropout rate of 10 % and a study power of
80 %, a proposed sample size of 104 evaluable subjects
was considered sufficient to detect a clinically and statis-
tically significant change in 6MWD from baseline to
week 12 of 23 m with a standard deviation of 83 m [7].
Improvement in 6MWD was assessed using paired T-
test, plasma NT-proBNP levels and BDI were assessed
using Wilcoxon Signed-Rank test. WHO FC and echo-
cardiography outcomes were summarised descriptively.
Last observation carry forward (LOCF) method of im-
putation for missing data was used for 6MWD, WHO
FC and BDI evaluations. The clinical worsening events
were summarised and the Kaplan-Meier analysis was
performed. All the safety data was summarised descrip-
tively. Subgroup analyses for the efficacy data was per-
formed based on gender, subjects having PAH associated
with connective tissue diseases, and subjects receiving
10 mg ambrisentan treatment.
The Intent-to-treat (ITT) population was used for ana-
lysis of efficacy and demographic/baseline characteris-
tics. It included all subjects who received at least one
dose of ambrisentan and had an efficacy assessment per-
formed both at baseline and after administration of the
ambrisentan. The safety population comprised of all sub-
jects who received at least one dose of ambrisentan.
An adhoc analysis was performed to determine the
effect of ambrisentan on heart rate recovery at 1 min
(HRR1min), 2 min (HRR2 min), and 3 min (HRR3min) after
exercise. HRR1min,/2 min/3 min is defined as the difference
in heart rate at the end of 6MWT and at 1/2/3 min after
completion of the 6MWT.
Results
Patient disposition and baseline characteristics
Of the 134 subjects, 133 were included in the ITT popu-
lation set (one subject was not included in ITT popula-
tion due to no efficacy assessment performed after
treatment). A total 10 out of 133 subjects (7.5 %) with-
drew from the study. The majority of the withdrawals
were due to AEs (n = 5) which are detailed in the safety
section. The study population mainly comprised of
women (85 %), with mean age of 36 (SD 10.25) years.
PAH associated with connective tissue disease was the
most prevalent diagnosis at baseline; subjects either had
WHO FC II or III symptoms (Table 1). Concomitant
medications were used pre-treatment and on-treatment
by 76.9 and 85.1 % of subjects respectively, the most
frequently used medications pre-treatment and on-
treatment were same (furosemide, spironolactone, di-
goxin). Only one (0.7 %) subject was taking CCB during
the study period.
All subjects (n = 134) received at least a single dose of
ambrisentan. Overall, mean (SD) duration of exposure
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was 161.7 (27.13) days, and the average daily dose was
6.27 (1.24) mg (Table 2).
Efficacy
A significant increase in 6MWD from baseline (mean
377.1 m) was noted after 12 (53.6 m, p < 0.001) and 24
(64.4 m, p < 0.001) weeks of ambrisentan treatment
(Table 3). A significant improvement in 6MWD was
noted as early as week 4 and continued for all subse-
quent time points (Fig. 1 and Table 3). Plasma NT-
proBNP levels decreased significantly with ambrisentan
treatment at week 12 (−861 ng/L, p < 0.001) and week
24 (−806 ng/L, p < 0.001) compared to baseline (mean
1601 ng/L), both p <0.001.
A large proportion of subjects showed improvement in
the WHO FC from baseline; 44 subjects (33.1 %) at week
12 and 51 subjects (38.3 %) at week 24 showed an im-
provement by 1 class. Only 5 subjects showed worsening
of functional class by 24 weeks of treatment. Significant
improvement in BDI scores was observed at week 12
(decrease of 0.3 score, p < 0.001) and at week 24 (de-
crease of 0.2 score, p = 0.003) (Table 3). Echocardiog-
raphy parameters showed a trend towards improvement
at week 12 and 24 with ambrisentan treatment. A de-
crease (improvement) in pericardial effusion volume
from baseline was observed for 13 (12.0 %) subjects at
week 12 and for 18 (16.7 %) subjects at week 24. About
65 % of subjects showed no change in effusion volume
at week 12 and 24; few subjects (5 to 9 %) showed wors-
ening in pericardial effusion. Mean change (SD) in tri-
cuspid annular plane systolic excursion was +0.14 (0.31)
at week 12 and +0.15 (0.32) at week 24 compared to
baseline (mean 1.55 (0.33)). Mean change (SD) in sys-
tolic eccentricity index was −0.07 (0.41) at week 12 and
−0.13 (0.37) at week 24 compared to baseline (mean
1.90 (0.48)). Mean change (SD) in diastolic eccentricity
index was −0.08 (0.24) at week 12 and −0.07 (0.22) at
week 24 compared to baseline (mean 1.44 (0.25)).
Table 1 Demographic and baseline characteristics (ITT
population)
Ambrisentan (N = 133)
Age, years, mean (SD) 36 (10.3)
Gender, n (%)
Men/women 20 (15)/113 (85)
Ethnicity, n (%)
Not Hispanic or Latino ethnicity 133 (100)
BMI (kg/m2), mean (SD) 21.5 (3.2)
PAH classification, n (%)
PAH associated with connective tissue disease 71 (53.4)
Idiopathic PAH 47 (35.3)
PAH associated with congenital heart disease 12 (9.0)
Heritable PAH 3 (2.3)
6MWD, m, mean (SD) 377.1 (61.3)
WHO PAH functional classification, n (%)
Class II 70 (52.6)
Class III 63 (47.4)
BDI, mean (SD) 2.5 (1.4)
NT-ProBNP (ng/L), mean (SD) 1600.7 (1832.84)
BMI body mass index, PAH pulmonary arterial hypertension, 6MWD 6-Minutes
Walk Distance, WHO World Health organization, NT-proBNP N-terminal pro B-
type natriuretic peptide, BDI Borg Dyspnoea Index, ITT intent-to-treat
Table 2 Extent of drug exposure during study





Combined Ambrisentana Ambrisentan 10 mg
Exposure (days) n 134 127 73
Mean (SD) 83.0 (9.13) 82.8 (5.59) 75.8 (16.02)
Median 85.0 83.0 83.0
Min, Max 31, 90 34, 94 27, 87
Range of exposure, n (%) n 134 127 73
<=28 days 0 0 2 (2.7)
29–56 days 5 (3.7) 2 (1.6) 12 (16.4)
57–84 days 37 (27.6) 90 (70.9) 44 (60.3)
> = 85 days 92 (68.7) 35 (27.6) 15 (20.5)
Average of daily dose (mg) n 134 127 73
Mean (SD) 4.95 (0.170) 7.81 (2.462) 10.11 (0.346)
Median 4.94 9.04 10.12
Min, Max 4.4, 6.5 4.8, 11.5 8.5, 11.5
aCombined for all subjects who received Ambrisentan 5 mg and Ambrisentan 10 mg in Dosage adjustment Period
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Subgroup analyses showed that the overall efficacy pat-
tern of ambrisentan in the subjects having PAH associ-
ated with connective tissue disease was similar to the
pattern noted in overall population. The primary out-
come measure of 6MWD was significantly (p < 0.001)
increased by 63.8 m and by 73.2 m at week 12 and 24,
respectively, following ambrisentan treatment in subjects
with PAH associated with connective tissue disease. This
increase was slightly greater than that noted for overall
population. The subgroup of subjects receiving 10 mg
dose of ambrisentan during dose-adjustment period
showed significant improvement in 6MWD at week 12
(53.9 m [95 % CI: 41.7 to 66.1; p < 0.001]) and week 24
(69.7 m [95 % CI: 48.1 to 91.3; p < 0.001]) after treat-
ment. The increase in 6MWD was similar to that noted
for overall population. Subgroup analysis by gender
showed that dmbrisentan achieved significant improve-
ment in 6MWD, NT-ProBNP, WHO FC and BDIin both
men and women. In general, men demonstrated a larger
improvement from baseline in 6MWD compared with
women. The 6MWD was significantly (p < 0.001) in-
creased by 78.2 and 94.2 m in men and by 49.2 and 59.1
m in women at week 12 and 24, respectively. Improve-
ments noted in other parameters were however larger in
women than in men.
The HRR1min, 2 min, 3 min after exercise was faster fol-
lowing ambrisentan treatment at week 12 and 24 than
that noted at baseline (difference in heart rate over 1 to
3 mins post exercise ranged from 9.0 to 18.2 beats/min
at baseline, 10.8 to 20.2 beats/min at week 12 and 11.7
to 21.2 beats/min at week 24). A significant decrease of
the heart rate difference from baseline was noted only at
1 and 2 min post exercise after 24 weeks of ambrisentan
treatment (change in heart rate from baseline: −2.7 and
−3.3 beats/min at 1 and 2 mins post exercise at week 24,
respectively; p < 0.05).
Safety
A total of 91 out of 134 subjects (67.9 %) experienced at
least one AE during the study. As shown in Table 4, the
most common AEs regardless of relationship to study
drug were peripheral oedema, flushing, elevations of
Table 3 Change from baseline in 6MWD, BDI scores, WHO
functional classification and NT-proBNP levels after ambrisentan
treatment (ITT population)
Efficacy measures Baseline Week 12 Week 24
6MWD, meters (LOCF)
N 133 133 133
Mean (SD) 377.1 (61.30) +53.6 (64.50) +64.4 (91.17)





N 133 133 133
Mean (SD) 2.5 (1.37) −0.3 (1.52) −0.2 (1.95)
P value (95 % CI) <0.001 0.003
WHO functional classification, n (%) (LOCF)
N - 133 133
Improved by class
1/2
44 (33.1)/0 51 (38.3)/0
No change 84 (63.2) 77 (57.9)
Worsened by class
1/2
4 (3.0)/1 (0.8) 3 (2.3)/2 (1.5)
NT-proBNP levels, ng/L (Observed data)







P values (95 % CI) P < 0.001 P < 0.001
LOCF last observation carry forward, 6MWD 6-Minutes Walk Distance, BDI Borg
Dyspnoea Index, WHO World Health Organisation, ITT intent-to-treat
*P-value calculated from paired T-test. P-value was derived from Wilcoxon
signed-rank test. P < 0.05 indicated statistically significant difference
from baseline
Fig. 1 Improvement in 6MWD over 24 weeks following ambrisentan treatment (LOCF) (ITT population). Note: Mean (SD) baseline value for 6MWD
was 377.1 (61.30) meters. AMB: ambrisentan
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hepatic enzymes (ALT, AST, GGT) or bilirubin, head-
ache, and nausea. Most of these events were of mild to
moderate intensity. Drug-related events were noted in
46 out of 134 subjects (34.3 %), the most frequent were
peripheral oedema (11.2 % [15 out of 134 subjects]) and
flushing (8.2 % [11 out of 134 subjects]). The other indi-
vidual drug-related events occurred in less than 3 pa-
tients each. Up to week 24, clinical worsening of PAH
occurred in 4 subjects. More than 95 % of study popula-
tion did not have worsening of PAH after 12 and
24 weeks of treatment (Fig. 2). Four deaths (including 1
subject died after 2 months of hospitalization for cardiac
failure) were reported during the study, all were related
to clinical worsening (sudden cardiac death [n = 2], cere-
bral haemorrhage [n = 1], cardiac failure [n = 1]). Five
subjects discontinued the study due to AEs which
included sudden cardiac death (n = 2), cardiac failure (n
= 1), cerebral haemorrhage (n = 1), and generalized
oedema (n = 1); none of these events were considered re-
lated to ambrisentan treatment. Eleven subjects (8.2 %)
had a serious adverse event. Of these, only 1 event of
peripheral oedema was considered related to ambrisen-
tan treatment. No subjects experienced increases in ALT
and AST levels >3 × ULN or bilirubin > 2 × ULN. No
significant changes were noted in the hematology pa-
rameters. There were no clinically meaningful changes
in vital signs, ECG and physical examination.
Discussion
This study conducted in Chinese subjects predominantly
included subjects with PAH associated with connective
tissue disease and WHO FC II or III symptoms. The ma-
jority of the population in this study was women and
relatively young which was consistent with the earlier
global studies for ambrisentan. Ambrisentan treatment
in Chinese patients resulted in significant improvement
in several important clinical parameters such as exercise
capacity. In addition, over 24 weeks of ambrisentan
treatment, more than 95 % of patients did not have clin-
ical worsening of disease.
The 6MWD which measures the functional exercise
capacity was employed as the primary endpoint in this
study. Treatment with ambrisentan (5 mg) resulted in
significant improvement from baseline in 6MWD at
week12 (+53.6 [64.50] meters), incremental improve-
ments were noted up to week 24 (+64.4 [91.17] meters).
Dose adjustment was allowed upto 10 mg. Ambrisentan
further showed improvement in Borg Dyspnoea Index,
which is a visual analogue score used to quantify efforts
during 6MWT. Given the progressive nature of the
disease, the impact of ambrisentan on WHO FC was
noteworthy even though inclusion criteria required a
minimum of 150 m on the 6MWD and no greater than
Table 4 Most frequent (≥5 %) adverse events during
ambrisentan treatment (safety population) by maximum
Intensity
Adverse events Mild Moderate Severe Total
Any adverse events, n (%) 52
(38.8)
32 (23.9) 7 (5.2) 91
(67.9)
Oedema peripheral 10 (7.5) 5 (3.7) 0 15
(11.2)
Flushing 10 (7.5) 1 (0.7) 0 11 (8.2)
Alanine aminotransferase
increased
8 (6.0) 1 (0.7) 0 9 (6.7)
Aspartate aminotransferase
increased
7 (5.2) 2 (1.5) 0 9 (6.7)
Blood bilirubin increased 8 (6.0) 1 (0.7) 0 9 (6.7)
Gamma-glutamyltransferase
increased
4 (3.0) 3 (2.2) 0 7 (5.2)
Headache 7 (5.2) 0 0 7 (5.2)
Nausea 4 (3.0) 3 (2.2) 0 7 (5.2)
All the events of peripheral oedema and flushing were reported to be related
to the study drug
Fig. 2 Kaplan-Meier plot for time to clinical worsening (safety population)
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450 m. The majority of subjects maintained or had an
improvement in functional class after 12 and 24 weeks
treatment; only 5 subjects experienced worsening of
functional class by end of treatment period. The results
corroborated the clinical worsening outcomes which
showed about 95 % of subjects free from worsening after
12 and 24 weeks of treatment. The clinical benefits of
ambrisentan on the aforementioned parameters (6MWD,
WHO FC, BDI) were noted as early as week 4 and were
sustained up to week 24.
Improvements in cardiac function were also evident.
NT-proBNP plasma concentrations decreased signifi-
cantly with ambrisentan treatment. Increased plasma
NT-ProBNP levels are associated with right ventricular
systolic dysfunction, and increased risk of early death
[15]. There was a trend towards improvement in echo-
cardiography parameters which may suggest a potential
beneficial impact of ambrisentan treatment on heart
function. The heart rate recovery at 1 and 2 min post
exercise was faster following ambrisentan treatment at
week 24. This observation was of particular interest,
as heart rate recovery is known to be a strong pre-
dictor of clinical worsening and survival in subjects
with PAH [17].
Overall the efficacy noted in this study was consistent
with earlier pivotal studies in the western population
(6MWD improved by 51 m with ambrisentan 10 mg)
[7, 8, 18] and in studies conducted in Japanese populations
(6 MWD improved by 33.5 with ambrisentan 10 mg)
[19, 20]. Results of subgroup analyses conducted in this
study with subjects diagnosed with PAH associated with
connective tissue disease showed improvements in
efficacy parameters (6MWD, WHO FC, BDI and NT-
proBNP plasma levels) with ambrisentan treatment.
In terms of safety, most of the AEs observed in this
study were either mild or moderate in intensity. The types
and frequencies of AE for drug-related events were similar
to those noted in earlier studies in western as well as
Japanese populations [7, 8, 18–20]. Peripheral oedema was
the most frequently reported drug- related event and was
noted in 11.2 % of subjects. AEs leading to discontinuation
were few and were generally related to disease progres-
sion. Four subjects experienced disease progression, which
eventually led to death. Of note, none of the subjects had
any liver function abnormalities of clinical concern. ALT
and AST levels were below 3 fold the ULN even at the
highest dose tested (10 mg). Based on the safety profile
observed during the study, it appears that dose escalation
to 10 mg could be successfully achieved in this Chinese
population without any additional safety concerns. To a
large extent, the safety outcomes including the decrease in
clinical worsening with ambrisentan treatment in this
Chinese population was similar to the studies conducted
in western and Japanese subjects [7, 8, 18–20].
Although encouraging results have been obtained from
this study, the lack of a comparator group poses some
limitations on the conclusions that can be achieved.
Using a placebo-controlled design would not have been
ethically appropriate since there are approved PAH med-
ications available in China, while using the only available
active-control (bosentan) at the time of study start using
a non-inferiority design was unot feasible due to the
large sample size and differences in the approved indica-
tions for the two ERAs. Nevertheless, the efficacy and
safety results obtained from this study were in line with
the pivotal placebo-control trials in western populations.
Conclusions
In this study, ambrisentan at doses of 5 and 10 mg
showed significant improvement in the exercise capacity
and clinical worsening did not occur in more than 95 %
of patients after 24 weeks treatment in Chinese subjects.
Ambrisentan demonstrated a safety profile similar to
that observed in other populations, with no unexpected
drug-related adverse events or any new safety signals
noted during the study. Ambrisentan could be consid-
ered as an effective approach for management of PAH in
Chinese subjects.
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